In this edition of The Onco’Zine Brief Peter Hofland talks with Peter Keeling about Personalized Medicine, diagnostic testing, and the effect of Covid-19 on cancer and cancer diagnostics. Hofland and Keeling also talk about the world’s first Diagnostic Network for Precision Medicine.
Peter Keeling is the chief executive officer and Founder of Diaceutics. Since its founding, the company has built the world’s largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries.
The company recently launched the world’s first digital diagnostics platform solution. Diaceutics has launched this new platform – called --The Diagnostic Network® ---to help solve the many problems that exist today within the patient diagnosis process.
A proper diagnostic test is an essential step to ensure that a patient receives the most effective treatment.
Correctly diagnosing also leads to efficiently managing a patient’s disease, which, in turn, results in improved healthcare outcomes.
In contrast, the failure to diagnose a condition correctly can reduce the possibility of a good healthcare outcome and limit a patient's ability to fully recover.
Diaceutics’ network has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics. But more importantly, the platform is designed to get every patient the treatment he or she deserves.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief
For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.